| 87.15 -1.73 (-1.95%) | 04-25 10:11 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 114.2 | 1-year : | 133.39 |
| Resists | First : | 97.77 | Second : | 114.2 |
| Pivot price | 89.86  |
|||
| Supports | First : | 80.25 | Second : | 69.43 |
| MAs | MA(5) : | 87.62 |
MA(20) : | 86.02 |
| MA(100) : | 82.07 |
MA(250) : | 73.59 |
|
| MACD | MACD : | 2.1 |
Signal : | 2.3 |
| %K %D | K(14,3) : | 62.2 |
D(3) : | 62.1 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 99.62 | Low : | 36.41 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TMDX ] has closed above bottom band by 35.6%. Bollinger Bands are 6.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 91.07 - 91.59 | 91.59 - 92.06 |
| Low: | 85.42 - 85.97 | 85.97 - 86.47 |
| Close: | 88.07 - 88.97 | 88.97 - 89.79 |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Thu, 25 Apr 2024
TransMedics Group (STU:TMDX) 5-Year EBITDA Growth Rate : 23.00% (As of Dec. 2023) - GuruFocus.com
Wed, 24 Apr 2024
TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Australia
Wed, 24 Apr 2024
TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable - Simply Wall St
Mon, 22 Apr 2024
TransMedics (TMDX) Increases Yet Falls Behind Market: What Investors Need to Know - Zacks Investment Research
Fri, 19 Apr 2024
TransMedics Group: Founder Led Company With Solid Potential - Seeking Alpha
Mon, 15 Apr 2024
There's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 33 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 113.1 (%) |
| Shares Short | 5,990 (K) |
| Shares Short P.Month | 4,980 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.19 |
| Profit Margin | -10.4 % |
| Operating Margin | 5.6 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | -15.5 % |
| Qtrly Rev. Growth | 158.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.35 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -192 (M) |
| PE Ratio | -114.24 |
| PEG Ratio | 0 |
| Price to Book value | 20.94 |
| Price to Sales | 11.95 |
| Price to Cash Flow | -221.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|